Evidence map›Paper›PMID 34010501›Full record

ArticleChemistryOpen2021

Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics.

Shailima Rampogu, Gihwan Lee, Apoorva M Kulkarni, Donghwan Kim, Sanghwa Yoon, Myeong Ok Kim, Keun Woo Lee

Abstract read
In one paragraph

Article in ChemistryOpen, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shailima RampoguDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.
Gihwan LeeDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.
Apoorva M KulkarniDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.
Donghwan KimDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.
Sanghwa YoonDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.
Myeong Ok KimDivision of Life Science and Applied Life Science, College of Natural Sciences, Gyeongsang National University, Jinju, South Korea.
Keun Woo LeeDivision of Life Sciences, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju, 52828, South Korea.

Funding

Korean government (MSIT) NRF-2018M3A9A7057263Korean Government (MSIT) 2020M3E5D9080660National Research Foundation (NRF)
6 · The paper itself

Abstract

Scientists all over the world are facing a challenging task of finding effective therapeutics for the coronavirus disease (COVID-19). One of the fastest ways of finding putative drug candidates is the use of computational drug discovery approaches. The purpose of the current study is to retrieve natural compounds that have obeyed to drug-like properties as potential inhibitors. Computational molecular modelling techniques were employed to discover compounds with potential SARS-CoV-2 inhibition properties. Accordingly, the InterBioScreen (IBS) database was obtained and was prepared by minimizing the compounds. To the resultant compounds, the absorption, distribution, metabolism, excretion and toxicity (ADMET) and Lipinski's Rule of Five was applied to yield drug-like compounds. The obtained compounds were subjected to molecular dynamics simulation studies to evaluate their stabilities. In the current article, we have employed the docking based virtual screening method using InterBioScreen (IBS) natural compound database yielding two compounds has potential hits. These compounds have demonstrated higher binding affinity scores than the reference compound together with good pharmacokinetic properties. Additionally, the identified hits have displayed stable interaction results inferred by molecular dynamics simulation results. Taken together, we advocate the use of two natural compounds, STOCK1N-71493 and STOCK1N-45683 as SARS-CoV-2 treatment regime.

Indexed as

Antiviral AgentsBiological ProductsDrug DiscoveryEnzyme InhibitorsMethyltransferasesMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingSARS-CoV-2SoftwareViral Nonstructural ProteinsAntiviral AgentsBiological ProductsEnzyme InhibitorsMethyltransferasesNSP16 protein, SARS-CoV-2Viral Nonstructural Proteinscomputational studiesCOVID-19molecular dockingnatural compoundsSARS-CoV-2virtual screening

Identifiers

PMID34010501
PMCPMC8133350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.